Methods and compositions for bactericide, bacteriostatic and anti-inflammation

A composition and compound technology, applied in the field of sterilization or bacteriostasis, can solve problems such as side effects that are not suitable for use

Active Publication Date: 2007-08-29
BLUE BLOOD BIOTECH CORP
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional anti-inflammatory agents, such as corticosteroids and...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for bactericide, bacteriostatic and anti-inflammation
  • Methods and compositions for bactericide, bacteriostatic and anti-inflammation
  • Methods and compositions for bactericide, bacteriostatic and anti-inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Embodiment 1: the antibacterial action of DM to Propionibacterium acnes (Gram-positive anaerobic bacteria)

[0060] A DM stock solution was prepared at 500,000 ppm (50%). Add 0.25g DM to 250μl DMSO, stir until fully mixed. 500,000 ppm DM was then serially diluted.

[0061] A 5 ml culture of P. acnes grown in RCM (Enhanced Clostridium Medium) was centrifuged. Dilute 20 times with culture medium and adjust the concentration of bacterial cells to approximately OD 595 =0.1×10 6CFU / ml. Take an equal amount of 200 μl culture medium containing bacterial cells and add to each well of the 96-well plate. The culture medium containing bacterial cells was mixed with 2 μl DM, and each concentration was sampled in triplicate. Bacteria were cultured at 37°C for 96 hours under anaerobic conditions, and then the OD was measured 595 . MIC refers to the lowest concentration of an antimicrobial agent sufficient to inhibit bacterial growth (eg, growth inhibition).

[0062] 0.1ml ...

Embodiment 2

[0069] Embodiment 2: DM is to the antibacterial action of Bacteroides fragilis (gram-negative anaerobic bacteria)

[0070] Bacteroides fragilis was grown anaerobically in thiosulfate broth for 18-24 hours and used to prepare a Mac Faland 0.5 bacterial cell suspension. The 0.5 g / ml DMSO stock solution was diluted with anaerobic thiosulfate broth. Add 1000 μl of anaerobic thiosulfate broth to 1000 μl of DM, dilute it at a ratio of 1:1, and then place it in an oxygen-free incubator for 24 hours.

[0071] Table 3: MIC test of Bacteroides fragilis (minimum inhibitory concentration test, the DM unit of the test is expressed in ppm and percentage%)

[0072] (+: growth inhibition; -: no growth inhibition)

[0073] DM (ppm)

[0074] "Negative control" means that no DM was added to the thiosulfate broth containing the bacteria.

Embodiment 3

[0075] Embodiment 3: the antibacterial action of DM to Gram-positive aerobic bacteria Escherichia coli

[0076] The matrix used for the antimicrobial disc diffusion susceptibility test was made of Mueller Hinton II agar (Becton, Dickinson and Company, France).

[0077] Prepare Mueller Hinton II agar by suspending 38 g of Mueller Hinton II agar powder in 1 liter of double distilled water. The above agar was autoclaved at 121°C for 15 minutes. Then pour into each agar plate and wait to set. 100 μl containing 1 x 10 5 The culture medium of CFU Escherichia coli was spread on the agar plate and cultivated for 96 hours.

[0078] Table 4: Growth Inhibition of Gram-positive Aerobic Bacteria by DM Disc Diffusion: Escherichia coli lawns were cultured at 37°C for 96 hours.

[0079] DM concentration

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-alpha, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.

Description

technical field [0001] The present invention relates to a bactericidal or bacteriostatic method. The present invention also relates to methods for treating inflammation caused by tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) or monocyte chemoattractant protein-1 (MCP-1) produced by macrophages method. Background technique [0002] Acne develops in 90% of teenagers, but adults also develop acne within a short period of time in their 20s and 30s. Acne (or acne vulgaris) is a chronic inflammation or disease of the sebaceous glands and hair follicles. acnes) overgrowth and other causes. Acne usually occurs on the most exposed parts of the skin, such as the face, chest, back, neck, and upper arms. Symptoms are blackheads, pustules, lupus, nodules, or scars. [0003] Millions of people around the world suffer from acne. Currently used treatments have various drawbacks, including adverse patient reactions (eg, blistering, photosensitivity, anaphylaxis), no o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/439A61K9/06A61K9/08A61P31/04A61P17/10A61P17/02A61P29/00
CPCA61K31/485Y10S514/859A61P17/00A61P17/02A61P17/10A61P29/00A61P31/00A61P31/04A61P43/00A61K31/015
Inventor 江传箕苏辉斌吴华林施桂月
Owner BLUE BLOOD BIOTECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap